MabVax Therapeutics Holdings, Inc., is a clinical-stage biotechnology company focused on the development of a pipeline of human monoclonal antibody products that are based on the protective immune responses generated by patients who have been immunized against targeted cancers with our proprietary vaccines.​

• We are currently in a Phase I trial with our lead candidate HuMab-5B1 (MVT-5873) an immunotherapy for patients with metastatic pancreatic cancer. Preparations are also underway to begin a second Phase I trial in May 2016, which will evaluate [Zr-89]-HuMab-581 (MVT-2163) as a next-generation PET imaging agent for the diagnosis and management of pancreatic cancer. ​

• We have a robust antibody discovery platform with multiple fully developed human antibody leads to 11 targets. Our leads are developed from our exclusive license with Memorial Sloan Kettering Cancer Center.

• MabVax also has two cancer vaccines targeting recurrent sarcoma and ovarian cancer in proof-of-concept Phase II multicenter clinical trials.​

• Members of our executive management team and board of directors all have significant experience in the development of drugs and diagnostics.

>Read More about MabVax Therapeutics

BIO CEO & Investor Conference Webcast
To Access the  Webcast  CLICK HERE
To view the presentation CLICK HERE


HuMab 5B1 Program 

Shareholder Letter 

Fact Sheet 

Corporate Presentation 

   Sign up for Email Alerts

Be the first to get breaking news 


 Shareholder Letter: 

2015 MabVax Shareholder Letter.pdf 2015 MabVax Shareholder Letter.pdf
Size : 170.929 Kb
Type : pdf

Investor Presentation: 


Loading data...
MabVax Therapeutics

Contact Us: MabVax Therapeutics
 11535 Sorrento Valley Road Suite 400
San Diego, California, 92121   (858) - 259 - 9405
email: info@mabvax.com

  © 2015, MabVax Therapeutics. All Rights Reserved 
Privacy Policy     Terms of Use     Disclaimer     Sitemap